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Abstract. Background: To present the technique and dose
distribution of intraoperative radiotherapy (IORT) for
prostate cancer. Patients and Methods: Pelvic
lymphadenectomy, prostate IORT and radical retropubic
prostatectomy was performed in 11 prostate cancer patients.
Prostate thickness and rectum depth were measured with
intraoperative ultrasound. IORT was delivered by a mobile
linear accelerator in the operating room (electron beam, 12
Gy at 90% isodose). Results: The mean preoperative
probability of organ-confined disease was 10% (Memorial
Sloan Kettering Cancer Center nomograms). Mean prostate
thickness, width and length were 3.4 cm, 4.6 and 4.9 cm,
respectively. Mean rectum depth was 3.3 cm. Mean doses to
the posterior prostate capsule, 5-mm lateral prostate margins
and at the subsequent uretheral stump area were 4.6 Gy, 8.7
Gy and 11.3 Gy, respectively. Maximum mean rectal dose
was 4.9 Gy. Conclusion: IORT appeared a feasible approach
for prostate cancer, showing a satisfactory dose coverage to
the prostate bed with relatively low rectal dose. However,
high variability in dose distribution calls for further study of
patient selection criteria and dosimetry. 
Radical prostatectomy is a well-accepted treatment for
prostate cancer (1). Several retrospective series and two
recent large randomized trials demonstrated an improved
biochemical and clinical progression-free survival in
patients with positive margins or pT3 treated with
postoperative radiotherapy (2-4). External beam
postoperative irradiation (EBRT) consists of a seven week
schedule and may be correlated with significant side-
effects. Moreover, the geometric uncertainties in defining
the target area and organ motion issues may jeopardize the
benefit of postoperative radiotherapy (5). Alternative
approaches are being sought. Intraoperative radiotherapy
(IORT), usually combined with EBRT, has been used for
many years for various locally advanced tumors (6). This
approach offers several radiobiological, physical and
clinical advantages. Recently, IORT using an electron
beam (IOERT) has been proposed prospectively at the
European Institute of Oncology, Milan, Italy, for
intermediate- and high-risk prostate cancer patients,
candidates for radical prostatectomy. The aim of our study
was to present this IOERT technique and to analyze its
dose distribution. Toxicity as well as tumor control data
will be the subject of a future report when longer follow-up
data are available.
Patients and Methods 
Inclusion criteria. The inclusion criteria were as follows:
recommended age <70 years, good performance status with no
clinically relevant co-morbidities, biopsy-confirmed intermediate-
or high-risk cN0 cM0 prostate adenocarcinoma (7), preoperative
probability of organ-confined disease ≤25% (according to the
Memorial Sloan Kettering Cancer Center nomograms) (8), patient
preference for surgical therapy and written informed consent for
IOERT. Endocrine therapy was permitted. 
Treatment protocol. Diagnostic and staging procedures included
transrectal ultrasound (TRUS)-guided biopsy confirming prostate
adenocarcinoma, chest X-ray, bone scan, abdomino-pelvic
computed tomography (CT) or magnetic resonance imaging
(MRI), clinical evaluation (with digital rectal examination) and
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blood biochemistry. All cases were discussed on a multidisciplinary
basis. Patients were then examined by a radiation oncologist for a
pre-planning evaluation, with pelvic CT and TRUS, and written
informed consent was obtained. 
For the surgery, the patients were put in the supine position.
After pelvic lymphadenectomy, the IOERT field was prepared
by starting the anatomical radical prostatectomy according to the
Walsh technique (9-10) Four long wire landmarks of the lateral
prostate pedicles, apex and bladder neck were inserted through
and inside the perspex IOERT applicator. In this way, the whole
prostate could be included in the irradiation field. Immediately
before IOERT, transaxial and midsagittal ultrasound (US)
images were acquired (SSD-2000, ALOKA, Tokyo, Japan). The
prostate dimensions and rectum depth were measured in order
to properly select the beam energy and applicator size (depth
dose distribution had been determined in a water phantom
during the commissioning of the treatment unit). IOERT was
performed using a Liac (Info&Tech, Rome, Italy) mobile linear
accelerator, working in the operating room. Liac was installed at
our Institute in 2004 and is mostly used for partial breast
irradiation (11). It can deliver electron beams with nominal
energies of 4, 6, 8 or 10 MeV at a very high pulse dose (12-13).
Beams are collimated by perspex applicators (Figure 1), flat-
ended or beveled (15Æ, 30Æ, 45Æ), with an inner diameter ranging
from 3 to 12 cm; the nominal source to skin distance is 60 cm.
The prescribed IOERT dose was 12 Gy at 90% isodose
equivalent to the normalized total dose (NTD) of 46.3 Gy and
32 Gy calculated with a linear-quadratic formula, using an ·/‚
ratio of 1.5 Gy and 4 Gy, respectively (14-15). Such a
prescription was derived from our experience in IOERT as a
boost for early-stage breast cancer (13). Similar doses are
prescribed in other tumors (e.g. pancreatic, rectal cancers)
treated with IOERT boost (6). After the IOERT, the
prostatectomy was completed and the specimen was removed. 
Postoperative EBRT at a dose of 45 Gy in 25 fractions was
prescribed to the prostatic bed alone and the whole pelvis in case
of pT3-4pN0 and pN1 disease, respectively, and scheduled three
months after surgery. 
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Figure 1. The irradiated area as seen after positioning of the cylindrical applicator.
Results 
Patient and tumor characteristics. Between June 2005 and
December 2005, 11 prostate cancer patients were included
in the study (Table I). 
Intraoperative organ measurements. Mean prostate thickness,
width and length were 3.4 cm, 4.6 and 4.9 cm, respectively
(Table II). Close agreement between the intraoperative US-
based and the preoperative TRUS- and CT-based prostate
measurements was found (16), showing that the latter
imaging can be used a priori as a reliable indicator of the
feasibility of IOERT for each individual patient. 
Dosimetry analysis. The maximum available electron energy
(10 MeV) was used in ten cases (91%). Eight MeV energy
was selected in one case, where the prostate thickness was
limited (2.5 cm). The applicator size of 5, 6 and 7 cm
diameter was used in two, six and three patients,
respectively. A thirty degree bevel angle was chosen in all
cases, except one, where the 45Æ angle was preferred for
better conformity to the surgical bed (avoiding the obstacle
represented by the pubic arc).
Mean doses to the posterior prostate capsule, lateral
prostate margins (at a distance of 5 mm) and areas
corresponding to the future uretheral stump were 4.6 Gy,
8.7 Gy and 11.3 Gy, respectively (Table III). Maximum
rectal dose was 4.9 Gy as an average. The urinary bladder
(in particular the bladder neck) had to be partially included
in the treatment field, thus receiving the whole prescribed
dose in some areas.
We are aware that the linear-quadratic radiobiological
model has not yet been demonstrated to be valid for a single
high dose, however, no established alternative is available in
the literature. Therefore, NTD (normalized total dose) and
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Table I. Preoperative patient and tumour characteristics, postoperative
findings. 
Characteristic 
Number of patients 11




Biopsy based Gleason score
Mean 7.3
Range 6-9




Preoperative nomograms, mean (range)* 
Organ confined disease 10% (1-25%)
Extracapsular disease 39.5% (17-57%)
Seminal vesicles involvement 26% (11-40%)


























PSA, prostate-specific antigen; *according to the Memorial Sloan
Kettering nomograms (8); **according to D’Amico et al. (7); EBRT,
external beam radiotherapy; RTOG, Radiation Therapy Oncology Group.
Table II. Preoperative and intraoperative prostate and rectum measurements. 
Preoperative Preoperative Intraoperative
TRUS-based CT-based US 
measurement measurement measurement
Prostate thickness (cm)
Mean 3.1 3.4 3.4
Range 2.2-4.3 2.3-4.6 2.5-4.8
Prostate width (cm)
Mean 4.9 4.8 4.6
Range 3.4-6.2 3.2-6.2 3.4-5.6
Prostate length (cm)
Mean 4.2 4.5 4.9 
Range 3.7-5.0 3.8-5.7 4.1-6.0
Prostate volume* (cc) 
Mean 35.3 41.4 40.7 
Range 14.7-59.2 17.9-71.2 22.2-67.2 
Rectal depth (cm) Not evaluable Not evaluable
Mean 3.3
Range 2.5-4.4
TRUS, transrectal ultrasound; CT, computed tomography; US,
ultrasound; *prostate volume calculation= thickness x width x length x
0.532 (16).
BED (biologically equivalent dose) calculations using the
linear-quadratic model are reported in Table III (17).
Postoperative findings. Organ-confined disease (pT2 pN0)
was found in three patients (27%) (Table I). The mean
number of the examined lymph nodes was 16 (range: 8-34).
Seminal vesicle involvement, positive and close surgical
margins were found in three, three and two patients,
respectively, and peri-neural and vascular invasion in ten and
two cases, respectively. Based on the definitive histological
report, postoperative pelvic and prostatic bed EBRT was
prescribed in five and three patients, respectively. Adjuvant
endocrine therapy was proposed for seven patients. 
Early postoperative complications (occurring within 30
days after hospital discharge) included significant and
symptomatic lymphocele requiring percutaneous catheter
drainage in one patient and prolonged catheterization
(>14 days) due to a persistent anastomotic leakage in 3
patients. No patient developed acute urinary retention
after catheter removal. The median estimated blood loss
was 1000 ml (range, 200-3000 ml) requiring blood
transfusion in four patients. 
Discussion 
To our knowledge, our investigation represents one of the
first extensive reports on the use of IORT for prostate cancer.
Only early reports from two Japanese institutions (18-21) and
data published exclusively in an abstract form (22) are
available in the English language literature. In the early
Japanese reports, a transperineal approach was used and the
prostate was not removed after the procedure (18, 20). The
transperineal approach has many disadvantages (high risk of
rectal damage, no lymph node approach and a long lasting
perineal discomfort to the patient) and therefore has been
abandoned (21). More recently, at the Regina Elena
Institute, Rome, Italy, IOERT (22 Gy) over the anastomotic
site has been proposed after prostatectomy reconstruction
(22). In our series, IOERT was proposed as an anticipated
boost to the prostate bed to the dose of 12 Gy (performed
before the prostate removal). The rationale for such a
technique was to intraoperatively irradiate the whole surgical
bed (approximately 5 mm around the prostate), while sparing
the rectum as much as possible. In most cases, both endpoints
were satisfactorily achieved, however high variability in the
target and rectal doses was observed for each individual
patient and between patients. This can be partially explained
by the non-uniform thickness of the target and electron beam
dosimetry. The clinical relevance of these well-known
limitations of IOERT has not yet been established (6). Better
dosimetric results could be obtained if more rigid patient
selection criteria are used. For example, based on the
preoperative CT measurements, cases showing a prostate
wider than 5 cm or thicker than 3.5 cm (approximately 40%
of depth dose for 10 MeV electron beams and 30Æ bevel
angle applicator) should be excluded. In this context, the
availability of higher electron energies could be helpful (23).
A completely different approach could consist of IOERT
following (instead of before) the prostatectomy, however such
a procedure could lead to a significant increase in the rectal
dose. An intraoperative US-based treatment planning system
and in vivo dosimetry (using real-time micro-MOSFET
detectors) could be helpful (12).
In our protocol IOERT was used as an anticipated boost,
and prostatic bed or pelvic EBRT was scheduled three months
after the surgery for all locally advanced patients (pT3-4 or
pN1, respectively). The prescribed IOERT dose of 12 Gy at
the 90% isodose is equivalent to the normalized dose of 56.2
Gy (·/‚ ratio 1.5 Gy) (14-15). The mean dose delivered to the
prostate bed was 8.7 Gy which is equivalent to 25.4 Gy given
with a conventionally fractionated regimen. Therefore, the
sum of 45 Gy prescribed postoperatively and 25 Gy given
intraoperatively is comparable to the doses prescribed for
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Table III. Dosimetry results, normalized total doses and biologically
equivalent doses [see text for explanation (14-15, 17)].
Dose NTD (Gy) BED (Gy)
Prostate prescribed dose 12 Gy 
at 90% isodose (i.e. 13.3 Gy at 
the depth of dose maximum)
·/‚=1.5 Gy 56.2 131.2
·/‚=4 Gy 38.3 57.5
Mean posterior prostate capsule 
dose 4.6 Gy (range: 0.6-8.4 Gy) 
·/‚=1.5 Gy 8.0 18.7
·/‚=4 Gy 6.6 9.9
Mean lateral prostate margin dose 
(+ 5 mm) 8.7 Gy (range: 2.4-12.0 Gy)
·/‚=1.5 Gy 25.4 59.2
·/‚=4 Gy 18.4 27.6
Mean urethral stump dose 11.3 Gy 
(range: 6.0-12.0 Gy)
·/‚=1.5 Gy 41.3 96.4
·/‚=4 Gy 28.8 43.2
Mean maximum rectal wall dose 
4.9 Gy (range: 0.6-8.4 Gy)
·/‚=4 Gy 7.3 10.9
·/‚=10 Gy 6.1 7.3
Maximum urinary bladder 
dose 13.3 Gy 
·/‚=5 Gy 34.8 48.7
NTD, normalized total dose; BED, biologically equivalent dose. 
postoperative EBRT (60-66 Gy) (2-3). However, these
calculations should be interpreted cautiously, since the data
on the radiation response of prostate cancer and late tissue
responses are not yet clear (14-15, 24). Importantly, there are
numerous data demonstrating the high sensitivity of prostate
cancer cells to the fraction size (low ·/‚ ratio) (14-15). In
consequence, a high dose per fraction, as given with IOERT,
should potentially lead to a therapeutic gain. This gain would
be even more pronounced if the prostate cancer ·/‚ ratio is
lower than that of the late responding tissues (14, 24). 
Future IOERT protocol modifications are considered. In
particular, precise information on the lymph node status
could allow two different therapeutic approaches. In those
patients with lymph node metastases, prostate IOERT could
be delivered as an anticipated boost followed by EBRT to
the pelvis. In pN0 patients, IOERT could be delivered as an
exclusive adjuvant radiotherapy, obviously up to a higher
dose than that prescribed in the current protocol (such
IOERT dose escalation requires further optimization of
rectal dosimetry and shielding). Once the feasibility of
IOERT is demonstrated, the equivalence of exclusive
IOERT and postoperative seven-week irradiation should be
studied in controlled prospective trials (as is already
ongoing in breast cancer) (6). The results of such trials, if
the equivalence of the two modalities is shown, might have
important impact on radiotherapy logistic and economic
aspects, as well as on the patient’s convenience. 
No further EBRT was proposed in our protocol for the
pT2 pN0 patients with clear surgical margins (three out of
11 cases). The benefit of any adjuvant radiotherapy in this
population has not been established. Therefore, to avoid
potential overtreatment (adjuvant IOERT in low stage
cancer), a more reliable preoperative staging and nomogram
cut-off level should be used. Routine preoperative pelvic
and/or endorectal coil MRI could be useful (25). Moreover,
the probability of pathologically organ-confined disease
should be low (for example, less than 10% instead of 25%
used in the present study) (8). More recent nomograms on
specific prediction of extracapsular extension may also be
useful (26). Ideally, the best candidates for IOERT would be
those patients with pT3 pN0 disease, for which the addition
of radiotherapy after surgery improves outcome (2-4). The
role of adjuvant radiotherapy in other patient populations
(pT2 pN0, pT4pN0 or any pN1 cases) is not yet clear. 
Since our study was planned to test the feasibility and
technical aspects of IOERT, hormonal manipulation was
permitted. This can make an accurate evaluation of the
pathological specimen difficult (due to possible downstaging),
as can be the assessment of the clinical outcome in
short/medium terms (27). Future study on the use of IOERT
in prostate cancer should therefore include well-defined
criteria for hormonal treatment. Another critical aspect of any
combined treatment is timing. In our study, postoperative
EBRT was scheduled three months after surgery,
corresponding to the recovery from surgery and the absence
of major voiding problems (2-3). From the radiobiological
point of view, such a time gap may reduce the efficacy and this
aspect should be addressed in future IOERT studies.
Importantly, the impact of IOERT on the peri- and early
postoperative complication rate seems negligible. Indeed, both
the rate of lymphocoele and blood loss data remain similar as
in the reports on large series treated with prostatectomy and
lymphoadenectomy without IOERT (28-29).
Conclusion
Our pilot study showed that IOERT delivered immediately
before prostatectomy appeared a feasible approach for
locally advanced prostate cancer, leading to a satisfactory
dose coverage to the prostate bed with relatively low rectal
dose. However, the high variability in dose distribution calls
for further study on better patient selection and dosimetry.
Careful analysis of the clinical outcome is warranted to
define the role of IOERT in prostate cancer.
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